BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

SQURPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

SQURPHARMA 24-Mar-2020

The Company has informed that the Board of Directors has approved agreements with M/s Renata Oncology Ltd. and M/s Apex Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of the Company to meet increased demand of existing products and to introduce new products.

SQURPHARMA 27-Feb-2020

Mr. Anjan Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 21.01.2020.

SQURPHARMA 27-Feb-2020

Mrs. Ratna Patra, one of the Directors of the Company, has further reported that she has completed her buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 21.01.2020.

SQURPHARMA 23-Feb-2020

Mr. Tapan Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 16.01.2020.

SQURPHARMA 23-Feb-2020

Samuel S Chowdhury, one of the Directors of the Company, has further reported that he has completed his buying of 3,00,000 shares of the Company at prevailing market price through Stock Exchanges (DSE & CSE) as per declaration disseminated on 16.01.2020.

SQURPHARMA 18-Feb-2020

(Continuation news of SQURPHARMA): ii) Initial estimated total cost will be Tk. 350.00 crore and to be financed by internally generated funds by the Square Pharmaceuticals Ltd. /Sponsors of Square Lifesciences Ltd. and iii) It is expected that the project would be completed by June, 2023. (end)

SQURPHARMA 18-Feb-2020

The Company has informed that the Board of Directors has taken the following decisions i) The Company shall establish a virtually wholly owned subsidiary Company in the name and style of "Square Lifesciences Ltd." in order to manufacture pharmaceuticals Oral Solid Dosage products. (cont.)

SQURPHARMA 29-Jan-2020

(Q2 Un-audited): Consolidated EPS was Tk. 4.18 for October-December 2019 as against Tk. 3.70 for October-December 2018; Consolidated EPS was Tk. 8.16 for July-December 2019 as against Tk. 7.46 for July-December 2018. Consolidated NOCFPS was Tk. 5.88 for July-December 2019 as against Tk. 6.83 for July-December 2018. Consolidated NAV per share was Tk. 84.12 as on December 31, 2019 and Tk. 80.40 as on June 30, 2019.

SQURPHARMA 23-Jan-2020

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2020 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2019.

SQURPHARMA 21-Jan-2020

Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 3,00,000 shares of the Company at prevailing market price (in the Public Market) through Stock Exchanges (DSE & CSE) within next 30 working days.

Previous Next page